Correlation between VL gene use and clinical presentation
| VL gene family . | Cardiac . | Renal . | Other5-150 . | MM . | Sex, male/female . |
|---|---|---|---|---|---|
| κ | |||||
| Vκ I | 10 | 10 | 11 | 4 | 14/6 |
| Vκ II | 1 | 0 | 1 | 1 | 1/0 |
| Vκ IV | 3 | 3 | 2 | 0 | 3/2 |
| Total | 14 | 13 | 14 | 5 | 18/8 |
| λ | |||||
| Vλ I | 4 | 4 | 4 | 0 | 5/2 |
| Vλ II | 8 | 4 | 7 | 2 | 5/6 |
| Vλ III | 2 | 3 | 7 | 4 | 8/1 |
| Vλ VI | 2 | 5 | 0 | 0 | 3/2 |
| Total | 16 | 16 | 18 | 6 | 21/11 |
| Grand total, κ + λ | 30 | 29 | 32 | 11 | 39/19 |
| VL gene family . | Cardiac . | Renal . | Other5-150 . | MM . | Sex, male/female . |
|---|---|---|---|---|---|
| κ | |||||
| Vκ I | 10 | 10 | 11 | 4 | 14/6 |
| Vκ II | 1 | 0 | 1 | 1 | 1/0 |
| Vκ IV | 3 | 3 | 2 | 0 | 3/2 |
| Total | 14 | 13 | 14 | 5 | 18/8 |
| λ | |||||
| Vλ I | 4 | 4 | 4 | 0 | 5/2 |
| Vλ II | 8 | 4 | 7 | 2 | 5/6 |
| Vλ III | 2 | 3 | 7 | 4 | 8/1 |
| Vλ VI | 2 | 5 | 0 | 0 | 3/2 |
| Total | 16 | 16 | 18 | 6 | 21/11 |
| Grand total, κ + λ | 30 | 29 | 32 | 11 | 39/19 |
Both the VL gene family and the germ-line gene were established for each patient, excluding 2 AL κ patients. The number of patients in each clinical category is represented based on V gene use. The clinical groups are not mutually exclusive.
Other indicates neurologic, GI, pulmonary, hepatic, and soft-tissue AL.